within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP53_OmbitasvirParitaprevirAndRitonavir;

model OmbitasvirParitaprevirAndRitonavir
  extends Pharmacolibrary.Drugs.ATC.J.J05AP53;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AP53</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ombitasvir, paritaprevir, and ritonavir is a fixed-dose combination antiviral medication used in the treatment of chronic hepatitis C virus (HCV) infection. Ombitasvir is an NS5A inhibitor, paritaprevir is an NS3/4A protease inhibitor, and ritonavir acts as a pharmacokinetic enhancer by inhibiting CYP3A-mediated metabolism of paritaprevir. This combination is approved for use in many countries and was commonly marketed as part of the Viekira Pak regimen.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration of the co-formulated combination under fed conditions.</p><h4>References</h4><ol><li><p>Flisiak, R, &amp; Flisiak-Jackiewicz, M (2017). Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. <i>Expert review of gastroenterology &amp; hepatology</i> 11(6) 559–567. DOI:<a href=\"https://doi.org/10.1080/17474124.2017.1309284\">10.1080/17474124.2017.1309284</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28317409/\">https://pubmed.ncbi.nlm.nih.gov/28317409</a></p></li><li><p>Gopalakrishnan, SM, et al., &amp; Menon, RM (2017). Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection. <i>Clinical pharmacokinetics</i> 56(1) 1–10. DOI:<a href=\"https://doi.org/10.1007/s40262-016-0423-2\">10.1007/s40262-016-0423-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27314261/\">https://pubmed.ncbi.nlm.nih.gov/27314261</a></p></li><li><p>Mensing, S, et al., &amp; Dutta, S (2016). Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. <i>The AAPS journal</i> 18(1) 270–280. DOI:<a href=\"https://doi.org/10.1208/s12248-015-9846-1\">10.1208/s12248-015-9846-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26597291/\">https://pubmed.ncbi.nlm.nih.gov/26597291</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end OmbitasvirParitaprevirAndRitonavir;
